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ABSTRACT 
Nissen and Bullemer (1987) developed the serial reaction time (SRT) task to measure 
attention in humans. The SRT task in rats is typically modeled after studies with humans 
and uses repeated or random sequences to test anticipatory reactions. In the current study, 
paraquat (PQ)-induced Parkinson‟s disease (PD) model in Long-Evans hooded rats was 
used to examine the rats‟ sequential learning. A water-soluble formulation of coenzyme 
Q10 (WS- CoQ10) was used as a therapeutic agent. Rats were induced with Parkinson‟s 
disease via the administration of paraquat. The aim of this study was to study the 
neuroprotective effects of CoQ10 using the SRT task to measure sequence performance in 
rats. The results indicated that the rats were much faster in responding to fixed sequences 
compared to random sequences. However, this study did not find significant results to 
indicate that exposure of paraquat with or without a neuroprotective agent, WS-CoQ10 
affected serial reaction performance. The implications of these findings are discussed 
with suggestions for further research with this task.
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CHAPTER I 
INTRODUCTION 
One of the common motor disorders affecting between 80,000 to 100,000 
Canadians is Parkinson‟s disease (PD), which results in the loss of dopamine-producing 
brain cells present in the substantia nigra pars compacta region of the brain. Much of the 
information regarding the etiology and pathogenesis of PD has been obtained from 
clinical, postmortem and epidemiological studies. Currently, the goals of therapy in PD 
are to maintain function and quality of life by treating its symptoms while trying to avoid 
or minimize any drug-induced complications. To date, levodopa is the most effective 
treatment for symptom relief in PD.  The aim of all dopaminergic strategies is to restore 
dopamine transmission in the striatum which is accomplished by stimulating postsynaptic 
receptors (directly with dopamine agonists), increasing dopamine precursor availability 
(levodopa), blocking the metabolism of levodopa in the brain, and blocking the 
catabolism of dopamine at the presynaptic terminal. Treatment however, does not reverse 
the morphologic changes and fails to arrest the progression of the disease. As the disease 
progresses, drug therapies tend to become less effective and symptoms become more 
difficult to manage.  Thus the priority must be to move beyond symptom control and 
develop neuroprotective therapies. Unfortunately, no such therapy is currently available, 
leaving this area open for further research.  
To make a model of neurodegeneration functionally relevant, a behavioural 
component is necessary. Along with various motor gaiting and balancing tasks, the serial 
reaction time task (SRT) may prove to be one of the most important assessment tools as it 
combines motor function skills with attentional and other cognitive capacities. The SRT 
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task consists of a sequence of a connected series of events that engages processes 
supporting the temporal organization of behaviour, the formation of high-order 
associations, and the prediction of future events (Chafee & Ashe, 2007; Keele et al., 
2004).  Moreover this test is easy to administer and manipulated to assess a patient‟s 
attention and other cognitive abilities as a function of the type and severity of his/her 
neurodegenerative disorder.  Despite such advantages, many inconsistent findings have 
been reported from studies employing this test on human patients with PD.  The use of 
different samples of patient populations at uncontrolled different stages of the disease 
have made comparisons between studies for replication of effects difficult to obtain. 
Therefore developing animal models has become imperative to (a) better understand of 
the pathogenesis of PD and for (b) preclinical testing of possible neuroprotective 
therapeutics to treat PD. Moreover, in animal models, it may be easier to control the 
degeneration of dopamine neurons with dose-specific exposure to neurotoxins like 
paraquat. Rodents are a common choice of animal used to study PD, they have a short life 
span and comparative brain structures with humans. In the neurological sciences, rodents 
have proved to be an important tool for the study of neural development, diseases, 
neurodegeneration, addiction, and general principles of cognitive behaviour. Given that 
rodents are a common choice of animal model to investigate neurodegeneration, we 
sought to use an SRT preparation derived from Eckart et al. (2010), who reported specific 
effects on SRT performance from lesions to dopamine areas of the rat‟s brain.  
Recent studies suggest that PD may arise from a combination of genetic 
susceptibility and exposure to environmental toxins (McCormack et al., 2002). Several 
environmental risk factors such as metals and herbicides have been linked to the greater 
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incidence and progression of PD (Dinis-Oliveira et al., 2006). Among these factors, the 
herbicide paraquat (PQ) shows a clear neurotoxicity in the central nervous system (CNS). 
Sub-lethal doses of this toxin have been shown to have targeted effects on dopamine 
neurons in the substantia nigra. PQ was chosen as the toxin to induce Parkinsonism in the 
current study because it is an environmental toxin associated with increased incidence of 
PD in areas where it has been used in agriculture (Liou et al. 1997) and also because it‟s 
chemical structure is similar to that of the synthetic narcotic MPTP (1-methyl-4-phenyl-1, 
2, 3, 6-tetrahydropyridine) known to have neuro-degenerative effects in the substantia 
nigra pars compacta (SNc) (Norris et al. 2007). Consideration of PQ as a candidate 
neurotoxicant requires that systemic delivery not only produces dopamine (DA) neuron 
loss in the substantia niagra (SN) but also exhibits the resultant behavioural effects  
reflecting dopamine depletion.  
CoQ10 is known to be a powerful antioxidant that reduces oxidative stress in in-
vitro preparations (Beal, 2003b). This in-vitro neuroprotectant has recently been shown to 
have an in-vivo prophylactic effect in rats exposed to PQ and therefore might also have a 
post-exposure therapeutic effect.  This possibility could lead to important clinical 
applications for preventing further loss of dopamine producing neurons in human PD 
patients. Therefore the major goals of the current study are (a) to examine signal 
sequence factors that affect rats‟ SRT performance, (b) to determine how such 
performance is affected by rats‟ exposure to PQ, and (c) to determine whether post-PQ 
exposure treatment with CoQ10 can ameliorate any SRT behavioral changes.  We note 
that this experiment is part of a larger preclinical study on the therapeutic effects of 
CoQ10 conducted in the University of Windsor‟s biochemistry department by Facecchia 
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et al. who are carrying out the biochemical assays on the brain tissue of these animals 
following our laboratory‟s behavioural assessments. 
In the next chapter, we discuss in further detail rats‟ serial pattern learning, PD 
and animal models of this disorder, and mechanisms of neuroprotection by CoQ10.  
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CHAPTER II 
REVIEW OF LITERATURE 
Parkinson’s Disease 
Epidemiology 
Parkinson‟s disease (PD) is one of the most common degenerative disorders of the 
nervous system. Occurring in about 1% of people over the age of 65, its peak age of onset 
is in the 60s (range is 35 to 85 years) and the course of the illness ranges between 10 and 
25 years (Kasper et al., 2005). Familial clusters of autosomal dominant and recessive 
forms of PD comprise approximately 5% of cases (Cory-Slechta et al., 2005). These 
cases are characterized by an earlier age of onset (typically before age 50) and a longer 
course than the more typical sporadic PD.   
Clinical Features 
An accurate diagnosis of PD can usually be made (with some confidence) in 
patients who present with rest tremor, rigidity and bradykinesia. Tremor is particularly 
important because it is found in 85% of patients with PD (Kasper et al., 2005). A 
unilateral and gradual onset of symptoms further supports the diagnosis. Masked faces, 
decreased eye blinking, stooped posture and decreased arm swing are some of the early 
symptoms of this disease. The most disabling feature of PD is bradykinesia, which 
interferes with all aspects of daily living. Fine motor control is also impaired as noted by 
a decrease in manual dexterity and handwriting (micrographia). Rest tremor typically 
appears unilaterally, first distally, involving the digits and wrist, where it may have a “pill 
rolling” character. Tremor usually spreads proximally, ipsilaterally and occasionally to 
the leg before crossing to the other side after a year or more after the onset of the disease. 
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Tremor may later appear in the lips, tongue and jaw. Rigidity is felt as a uniform 
resistance to passive movement about a joint throughout the full range of motion, giving 
rise to a characteristic “plastic” quality. Short lived and regular interruptions of resistance 
during passive movement may give rise to a “cogwheeling” sensation.  
Gait disturbance with shuffling and short steps is a prominent feature of PD. 
Festinating gait is a classic Parkinsonian sign and results from the combination of flexed 
posture and loss of postural reflexes which in turn cause the patient to accelerate in an 
effort to “catch up” with the body‟s center of gravity. Freezing of gait, a feature of more 
advanced PD, commonly occurs at the onset of locomotion (start hesitation), when 
attempting to change direction or turn around, and upon entering a narrow space. Postural 
instability is one of the most disabling features of advanced PD, contributing to falls and 
injuries and leading to major morbidity and mortality in this population.  
Non motor aspects of PD include depression, anxiety, cognitive impairment, sleep 
disturbances, sensory abnormalities and pain, loss of smell (anosmia), and disturbances of 
autonomic function. Together they may contribute as much to the burden of the disease 
as the more obvious motor abnormalities.  
Pathology 
On gross pathologic exam, the typical macroscopic findings in a PD brain are 
pallor of the substantia nigra and locus ceruleus due to degeneration of dopamine-
producing neurons in the substantia nigra pars compacta (SNc), a region within the 
midbrain (Corti et al., 2005). As mentioned previously, PD exhibits four classic 
symptoms: a resting tremor, muscular rigidity or stiffness, an inability to initiate 
movement, and generalized slowness of movement and postural instability. These 
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symptoms become fully developed after approximately 80% of the dopaminergic neurons 
in the SN are already lost, resulting in reduced synthesis and release of DA from the SNc 
region (Schober, 2004). Pharmacologic restoration of dopamine transmission is thus the 
basis for symptomatic drug treatment of PD.  
PD is assumed to be a multicentric disease. It is also believed that an association 
exists between the nigrostriatal degeneration and degenerative processes elsewhere in the 
central and peripheral nervous systems. Three possible mechanisms are hypothesized: 
damage to the SNc and other regions occurs simultaneously; the disease primarily begins 
in the SNc, which influences the involvement of other areas; or the involvement of the 
SNc occurs later in the disease (Lang & Lozano, 1998). Associated with this neuronal 
loss is the presence of large eosinophilic inclusions called “Lewy bodies,” which are 
found in the cytoplasm of the surviving neurons in the SN region. Lewy bodies are single 
or multiple, intracytoplasmic, eosinophilic round to elongated inclusions that often have a 
dense core surrounded by a pale halo (Cotran et al., 1999). They are abnormal aggregates 
made up of a series of proteins including neurofilaments, -synuclein fibrils, ubiquitin, 
parkin, and proteasomal elements and are a hallmark of genetic diseases such as PD 
(Schapira, 1999). 
Basal Ganglia 
Control of movement is highly varied in humans, from manipulating objects as 
light as a needle to swinging objects as heavy as a baseball bat to drive a ball across a 
field. Parkinson‟s disease (PD) is a disorder of “controlling” movements (Kolb, 2001). 
The brain areas that allow us to adjust the force of our movements include the basal 
ganglia (BG), which are a group of nuclei situated at the base of the forebrain and are 
8 
 
8 
connected with the cerebral cortex, thalamus and other brain areas. The BG has two 
subdivisions: (i) the rostral subdivision, containing the striatum (putamen and caudate 
nucleus), pas externa (GPe), and pars internal (GPi) segments of the globus pallidus;  and 
(ii) the caudal subdivision, containing the subthalamic nucleus (STN) and the substantia 
nigra (SN), which encompasses the SN pars compacta (SNc), SN pars reticulate (SNr) 
and the SN pars lateralis (SNI) (Obaso et al., 2008) (Figure 1). The BG are associated 
with a variety of functions, including voluntary motor control, procedural learning 
relating to routing behaviours, or “habits”, eye movements and most importantly, 
cognitive and emotional functions. In particular, the motor circuit has two entry points 
into the BG, the striatum and the STN, and an output, the GPi, which connects to the 
cortex via the motor thalamus (Obaso et al., 2008). The signals for intentional movements 
are initiated in the cerebral motor cortex and eventually reach the brain stem. From the 
brain stem the signals are transmitted to the muscles. Before this they reach the muscles, 
centers such as the cerebellum and the basal ganglia pose their influence on these signals. 
Both of these centers exert their influence on the final motor signals via the thalamus 
(Groenewegen, 2003). One theory holds that an inhibitory pathway and an excitatory 
pathway affect the activity of the motor cortex: (Alexander & Crutcher, 1990). Both these 
pathways converge on an area of the basal ganglia called the internal path of the globus 
pallidus (GPi). The GPi in turn, projects into the ventral thalamic nucleus and the 
thalamus projects to the motor cortex. The thalamic projections determine the size or 
force of a movement that the cortex produces and is influenced by the GPi. The GPi acts 
metaphorically like the volume dial on a radio because it controls the output thereby 
dictating whether a movement will be strong or weak. The direct projections to the GPi 
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are via the striatum and STN. Neurons in this pathway are the D1 dopamine receptor 
subtype and they provide a direct inhibitory effect on the GPi/SNr (Figure 2A). The 
indirect projections to the GPi are via the GPe. Neurons in this pathway are the D2 
dopamine receptor subtype, which cause the excitation of GPi/SNr (Figure 2B). The GPe 
regulates the motor output of the BG (Obaso, 2008). The output from the basal ganglia is 
influenced by the opposing effects of the direct and indirect pathways. If the activity in 
the indirect pathway dominates, the thalamus shuts down, and the cortex is unable to 
produce movement. If direct-pathway activity dominates, the thalamus can become 
overactive thereby amplifying the movements (Kolb, 2006). The DA deficiency that 
precedes PD leads to a cascade of functional changes in basal ganglia circuitry. 
Dopamine modifies striatal input and neuronal striatal activity, modulated GPe and GPi, 
and STN activity. The loss of DA neurons in PD disrupts the corticostriatal balance, 
which increases activity in the indirect circuit and ultimately reduces the activity in the 
direct circuit (Obaso, 2008). Therefore, PD is characterized by increased neuronal 
activity in the STN, GPi and SNr regions, leading to an inhibition of motor nuclei, which 
regulate the body‟s ability to execute smooth and controlled movements.  
Dopamine Pathways 
Dopamine (DA) is a catecholamine neurotransmitter present in all animals and 
readily available in the substantia nigra (SN). Dopamine has many functions in the brain; 
among them are vital roles in cognition, voluntary movement, motivation, punishment 
and reward. Dopamine is produced in several brain areas, including the SN and the 
ventral tegmental area (VTA) (Purves et al., 2007). Dopamine biosynthesis in the body 
begins with hydroxylation of the amino acid L-tyrosine to L-DOPA via the enzyme 
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tyrosine hydroxylase and then by decarboxylation of L-DOPA by dopa decarboxylase 
(Figure 3). In some neurons, DA is further processed into epinephrine and norepinephrine 
by dopamine beta-hydroxylase (Purves et al., 2007). In neurons, DA is packaged after 
synthesis into vesicles, which are then released into the synapse in response to a 
presynaptic action potential. In most areas of the brain, including the striatum and BG, 
DA is inactivated by reuptake via the dopamine transporter (DAT) (Dziedzicka-
Wasylewska, 2004), then is broken down by monoamine oxidase (MAOA and MAOB). 
Dopamine neurons are mostly present in the VTA of the midbrain, the SNc and 
the arcuate nucleus of the hypothalamus. This forms the neurotransmitter system, 
composed of axon projections to large areas of the brain which are divided into four 
major pathways: mesocortical, mesolimbic, nigrostriatal, and tuberoinfundibular 
pathways (Hung et al., 1995). The mesocortical pathway connects the VTA to the frontal 
lobe of the prefrontal cortex. Neurons with somas in the VTA project axons into the 
prefrontal cortex. This pathway is important for normal cognitive functions in the 
dorsolateral prefrontal cortex (part of the frontal lobe) and is involved in motivation, 
emotion, and aspects of learning and memory. The mesolimbic pathway carries DA from 
the VTA to the nucleus accumbens via the amygdala and hippocampus. The somas of the 
projecting neurons are in the VTA. This is widely known as the “reward” pathway. The 
tuberoinfundibular pathway runs from the hypothalamus to the pituitary gland. This 
pathway controls the secretion of prolactin from the anterior pituitary gland. Of particular 
importance is the nigrostriatal pathway, which runs from the SN to the neostriatum. 
Somas in the SN project axons into the caudate nucleus and putamen. This pathway is 
involved in the production of movement and belongs to a system called the basal ganglia 
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motor loop. The degeneration of the nigrostriatal dopaminergic pathway consequently 
results in a substantial striatal dopamine reduction, ultimately manifesting as symptoms 
of PD (Dinis-Oliveria et al., 2006). 
Etiology 
The etiology behind almost 95% of the cases of Parkinson‟s disease is unknown 
(Corti et al., 2005). The genetic inheritance in the origin of PD has been debated for more 
than a century. A study by Tanner et al. (1999) initiated a large twin study of PD by using 
the World War II twin‟s registry and the National Academy of Sciences registry. They 
studied concordance rates in both monozygotic and dizygotic twin pairs and used 19,842 
white males. These studies suggested that heredity plays an important role in cases with 
age of onset <50 years and a less important role in older patients. Four genes have been 
clearly linked to familial forms of PD. PARK 1 and PARK 5 lead to an autosomal 
dominant form of PD with typical features such as early age of onset and rapid 
progression of symptoms. PARK 1 encodes α-synuclein, leading to its abnormal 
aggregation. PARK 2 and PARK 7 lead to autosomal recessive disorders, also with 
atypical features, including juvenile forms of Parkinsonism (Kasper et al., 2005). PARK 
2 encodes parkin, an E3 ubiquitin protein ligase. Mutations in parkin appear to be the 
major cause of autosomal recessive PD. The identification of these and other mutations is 
proving invaluable in refining the correlation between genotypes and phenotypes, in 
generating animal models to study pathogenesis, and in identifying target pathways for 
possible therapeutic intervention. 
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Models to Study Parkinson’s disease 
Numerous concerns exist in studies involving patients with Parkinson‟s disease. 
Several studies have not succeeded in ruling out the possibility that the oxidative stress 
indices found in PD brains are anything other than the nonspecific expression of dying 
neurons. The postmortem tissue from end-stage PD is difficult to access due to ethical 
issues, and when these tissues were obtained, the studied samples lacked dopaminergic 
neurons. Another issue is that the majority of patients being used for postmortem studies 
are patients that have used a battery of drugs, such as L-DOPA, which, like dopamine, 
can readily auto-oxidize, giving rise to reactive oxygen species (ROS) (Parkinson‟s study 
group, 2004). This however does not imply that chronic use of this drug will induce PD, 
but does raise the concern that many observations from studies in humans may reflect 
artifacts from the treatments received by PD patients before their death. For these 
reasons, animal models of PD may be desirable in that they can provide controls against 
such confounds as well as provide pre-clinical tests of  therapeutic interventions. Since 
PD does not spontaneously develop in animals, neurotoxic agents have had to be used to 
induce the characteristic functional changes associated with PD. Some of the important 
toxin-induced models are discussed in the following section of this paper.  
MPTP Model 
Several causative factors have been found to induce Parkinsonism similar to that 
of idiopathic PD, including repeated head trauma, neuroleptic drugs, and manganese 
toxicity (Adler, 1999). In particular, the toxicant MPTP (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine), which was accidently discovered in the 1980s, resulted in the 
development of Parkinsonism symptoms in a small group of drug addicts (Langston et 
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al., 1983). These individuals injected themselves with the synthetic narcotic. The 
postmortem analysis of these addicts revealed a selective loss of neurons and Lewy 
body–like inclusions in the substantia nigra. These findings suggested that compounds 
similar to MPTP in structure or biological activity might be the primary cause of sporadic 
PD (Smeyne, 2005). By itself, MPTP is not toxic, but after reacting with monomine 
oxidase and converting to its toxic metabolite MPP+, it is believed to cause cell death by 
interfering with mitochondrial respiration (Costello et al., 2009) because it concentrates 
in mitochondria and inhibits complex-I of the electron transport chain.  
Several studies with MPTP have been conducted in nonhuman primates, rodents 
and cats although a majority of studies have been performed on rodents such as mice 
(Terzioglu, 2008). These studies showed that in various animals, MPTP induces damage 
to the dopaminergic neurons in the nigrostriatal pathway identical to that seen in PD 
(Bove et al., 2005). Various regimes and doses of MPTP were used to study PD 
(Betarbet, 2002). Chronic administration of MPTP induces about 50–60% loss of 
dopaminergic neurons in the substantia nigra. Susceptibility to this compound varies in 
different species. In the MPTP mouse model of PD, time-course experiments suggest that 
oxidative stress is an early event that may directly kill some of the dopaminergic neurons 
(Beal, 2001). Systemic MPTP administration in mice induces PD-like symptoms, 
including bradykinesia, rigidity and posture anomalies. 
Pesticide and Herbicide Induced PD Models 
Although the exact cause of PD remains unclear, numerous environmental risk 
factors have been identified in the modulation of the disease onset and/or its progression 
(De Monte, 2001, 2003; Di Monte et al., 2002). Several environmental agents are known 
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to cause nigrostriatal damage and may contribute to PD, namely, aluminum (Altschuler, 
1999); solvents such as methanol (Davis & Adair, 1999), and carbon monoxide (Klawans 
et al., 1982). Gorell et al. (1998) assessed exposure to pesticides, farming, well-water use, 
and rural living as risk factors for PD. They enrolled 144 patients with PD and 464 
control subjects from metropolitan Detroit. They found a significant association of 
occupational exposure to herbicides, insecticides and farming in general with PD. It has 
been hypothesized that many chemicals used in agriculture are capable of selectively 
targeting dopaminergic neurons, thereby accelerating the development of PD. Brown et 
al. (2006) conducted a literature search of 10 major studies and found a consistent 
association between exposure to pesticides and an increased risk of developing PD. 
Particular classes of pesticides found to be associated with PD include herbicides, in 
particular paraquat, and insecticides. Duration of exposure of more than 10 years was 
found to be a risk factor in developing PD.  
Paraquat Model of PD 
Paraquat (PQ), or 1, 1‟- Dimethyl-4, 4‟-bipyridinium, is a herbicide commonly used in 
many developing countries. This is a hydrophilic-charged molecule and therefore does 
not diffuse across the blood–brain barrier (BBB) (Denis-Oliveira et al., 2006) but rather 
through the neutral amino acid transporters. This toxicant is quick acting and kills plant 
tissue on contact. Paraquat is an agent known to induce Parkinsonian symptoms in 
humans and animals (Langston, 1983). Ingesting large dosages of paraquat causes liver, 
lung, heart, and kidney failure within several days to several weeks and may cause death. 
Moreover, studies have revealed a strong correlation between the amount of exposure to 
non-lethal dosages of paraquat and Parkinson‟s disease (Liou et al., 1997; Morano et al., 
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1994). Liou et al. (1997) explored environmental risk factors for PD in Taiwan. They 
recruited 120 patients with PD and 240 control participants in this study. All participants 
underwent structured interviews and open-ended questionnaires to obtain histories of 
their exposure to environmental factors, including place of residence, source of drinking 
water and environmental and occupational exposures to various agricultural chemicals. 
The authors suggested that there was an increased risk of PD associated with a history of 
living in rural environments, farming, and the use of herbicides and pesticides, 
specifically the agricultural use of paraquat (PQ). Moreover, the risk of PD was greater 
among participants who had used paraquat than in those who had used other types of 
herbicides and pesticides. It is important to note that the molecular structure of PQ is 
similar to that of MPP+ (Figure 5). Recent mammalian and yeast-cell experiments 
suggest that mitochondria actively take up PQ across their membranes where complex-I 
reduce it to the paraquat radical action that subsequently produced mitochondria-
damaging superoxide (Cocheme et al., 2008).  
Studies of PQ toxicity have recently focused on its CNS effects. Unlike the 
exposure to high levels of PQ that mainly produce pulmonary toxicity, chronic low levels 
resulting from prolonged exposure to nonpneumotoxic doses may produce damage to the 
basal ganglia. Toxic damage of the brain has been observed in patients who died from PQ 
poisoning (Grant et al., 1980; Hughes, 1988). Autopsy findings in cases of acute PQ 
poisoning showed cerebral damage with edema and neural death in the SN region. 
However, in these studies, the possibility of whether the observed tissue changes 
occurred either postmortem or as a consequence of anoxia due to respiratory dysfunction 
could not be ruled out (Grant et al., 1980). 
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Mechanism of Paraquat Toxicity  
One mechanism by the cellular toxicity of PQ is essentially due to its redox cycle 
which leads to the production of reactive oxygen species (ROS) (Castello et al., 2007). 
Paraquat is reduced, mainly by NADPH-cytochrome P-450 reductase (Clejan & 
Cederbaum, 1989). NADPH-cytochrome c reductase (Fernandez et al., 1995) and the 
mitochondrial complex 1, also known as NADH:ubiquinone oxidoreductase (Fukushima 
et al., 1993; Yamada & Fukushima, 1993) combine to form a PQ monocation free radical 
(PQ+). It is generally accepted that PQ uses cellular diaphoresis, which are a class of 
enzymes that transfer electrons from NAD (P) H to small molecules, such as PQ (Day et 
al., 1999). The PQ monocation free radical is then rapidly reoxidized in the presence of 
oxygen, generating the superoxide radical (O2-) (Bush et al., 1998). This then sets off a 
cascade of reactions leading to the generation of other ROS, mainly hydrogen peroxide 
(H2O2), hydroxyl radical (HO), and the consequent adverse cellular effects. Indeed, 
hydroxyl radicals (Bush et al., 1998) have been implicated in the initiation of membrane 
damage by lipid peroxidation during the exposure to PQ in vitro (Busch et al., 1998) and 
in vivo (Burk et al., 1980). These results were confirmed by McCarthy et al (2004) who 
investigated the mechanism of cell death of differentiated in vitro human neuroblastoma 
cells. They found that exposure to PQ produced cell death by causing oxidative stress and 
subsequent mitochondrial dysfunction (McCarthy et al., 2004).  
Paraquat has been found to selectively kill nigrostriatal dopaminergic neurons in 
in-vivo animal models (Suntres, 2002). This study revealed that paraquat induced cell 
death by causing oxidative stress. The details behind this interaction are still not clearly 
understood. Somayajulu et al (2009) concluded that PQ administration into rat‟s causes 
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the loss of DA neurons, specifically in the SNc. Results showed that with the doses of 10 
mg/kg of PQ, damage was caused specifically to the DA neurons in the SNc without 
producing any decrease in cells in other brain areas.  
Paraquat-Maneb Model 
Parkinson‟s disease has been reported to occur at higher rates among farmers and 
in rural populations, leading to the hypothesis that agricultural pesticides, such as 
rotenone, maneb (MB), as well as paraquat (PQ), might be causal agents. Additionally, 
data from epidemiological studies point to an association between increased PD risk and 
specific environments. Costello et al. (2008) investigated whether exposure to maneb 
(fungicide) and paraquat (herbicide) alone and in combination increased the risk of 
incidents of PD among residents of the Central Valley of California, an area well known 
for its intensive agriculture and potential for pesticide exposure. They conducted 
extensive interviews with 377 patients with PD and 755 eligible controls. The researchers 
collected information on pesticide use as far back as 1974. The authors found that during 
the period between 1974 and 1999 that agricultural application of both maneb and 
paraquat within 500 meters of residences greatly increased the risk of developing PD. 
Exposure to both pesticides during the earlier years studied also doubled the risk for older 
cases. Association was strong for “younger-onset” patients (≤60 years), who would have 
been children, teenagers, and/or young adults during the exposure period. Among those 
who were exposed in the earlier years, risk was increased more than two times with 
exposure to just one of the pesticides and more than four times with exposure to both 
pesticides. Consistent with some theories regarding the progression of PD pathology 
(Braak et al., 2003), these data suggest that the critical window of exposure to toxicants 
18 
 
18 
may be years before the onset of motor symptoms, which ultimately leads to a positive 
diagnosis. Human data are insufficient to support this claim for any specific pesticide, 
largely because of challenges in exposure assessment. Given the public health 
implications concerning risk factors for the development of PD, the study of the 
environmental factors involved in the etiology of PD has gained the renewed interest of 
the scientific and medical community.  
Experimental evidence of the neurotoxicity of such organic compounds has been 
demonstrated in mice and rats. Studies have shown exposure to PQ alone or in 
combination with MB results in loss of DA neurons in SNc and reduction in animals‟ 
general activity. Norris et al. (2007) found that exposure to a combination of the 
fungicide maneb and the herbicide paraquat in mice led to increased substantia nigra 
neuronal pathology. In that study, mutant human α-synuclein transgenic mice (M83) were 
treated with the pesticides paraquat and maneb, either alone or in combination. The 
researchers found that chronic treatment of M83 mice with both pesticides drastically 
increased neuronal α-synuclein pathology throughout the CNS, including the 
hippocampus, cerebellum, and sensory and auditory cortices. This study supports the 
notion that environmental factors causing nitrative damage are closely linked to 
mechanisms underlying the onset of Parkinson‟s- like neurodegeneration. Thiruchelvam 
et al. (2003) tested whether exposing mice to different herbicides and/or pesticides would 
produce Parkinsonism features. The authors used young adult mice of different age 
groups (6 weeks, 5 months, or 18 months old). Subjects were exposed to the herbicide 
paraquat, fungicide maneb, or paraquat and maneb. The results showed that paraquat and 
maneb induced reductions in locomotor activity and motor coordination. The 18-month-
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old mice were most affected and exhibited failure to recover 24 hours posttreatment. 
Progressive reductions in dopamine metabolites and dopamine turnover were exhibited, 
and numbers of nigrostriatal dopaminergic neurons were reduced in all age groups 
following exposure. Collectively, these data demonstrate enhanced sensitivity of the 
ageing nigrostriatal dopamine pathway to these pesticides, particularly the paraquat+ 
maneb group, resulting in irreversible and progressive neurotoxicity. Cicchetti et al. 
(2005) studied the effects of PQ and MB on dopaminergic (DA) neuron-glia, both in vitro 
and in vivo cultures in young adult rats. In vitro, PQ led to a loss of DA compared to non-
DA neurons and microglial activation in a dose-dependent manner. The addition of MB 
had no further effect nor did it lead to microglial activation when used alone. In vivo, 2-
month-old rats were subjected to intraperitoneal injections (IP) of placebo, PQ alone, or 
PQ in combination with MB, twice a week for 4 weeks, and then were sacrificed the day 
following the last injection. The results showed a significant loss of nigral DA neurons in 
both treatment groups. Microglial activation was seen in the substantia nigra of rats 
subjected to PQ with or without MB. The authors further conducted behavioural-speed 
and mobility testing, which measured the degree of hunchback position; speed testing 
consisted of determining the speed at which animals conducted daily grooming, moving, 
and exploring the cage; and mobility testing consisted of placing the animal on a trellis at 
a 45-degree angle and assessing the degree of akinesia or bradykinesia. The behavioural 
analyses showed a mixed pattern of motor impairments, which may have been due to 
early effects of DA neuronal loss and/or systemic effects associated with MB exposure in 
addition to PQ. This study concluded that exposure to PQ with or without MB induced 
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neurodegeneration, which is thought to occur via an early inflammatory response in 
young adult animals. 
Molecular Mechanisms Contributing to PD 
In Parkinson‟s disease, dopaminergic cells die due to a combination of factors 
including excitotoxicity, mitochondrial dysfunction, and oxidative stress. However, the 
exact mechanism of neurotoxicity is not yet fully known. A current available research in 
this area will be discussed below.   
Excitotoxicity 
One of the mechanisms of neurodegeneration in several neurological diseases 
(Dugan & Choi, 1999) is by the excitotoxicity induced by N-methyl-D-aspartate 
(NMDA) receptor over activation. Excitotoxins like NMDA and kainic acid which bind 
to these receptors as well as high levels of glutamate, can cause excitotoxicity by 
allowing high levels of calcium (Ca
2+
) ions to enter the cell. Glutamate is an excitatory 
neurotransmitter implicated in the development of the brain and synaptic plasticity 
(Sandu et al., 2003). In vivo studies on the mechanisms of PQ-induced toxicity in the 
striatum indicate that PQ stimulates glutamate efflux, initiating excitotoxicity mediated 
by reactive nitrogen species (RNS). Increasing evidence shows that the excitotoxic injury 
plays a critical role in the progressive degeneration of DA neurons in PD (Beal, 1998). 
PQ induces continuous dopamine overflow and a consequent reduction of dopamine 
synthesis (Dinis-Oliveira et al., 2006). However, no direct evidence has been found to 
indicate excitotoxicity in PD.  
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Mitochondrial Dysfunction in PD 
Many lines of research point to possible mitochondrial dysfunction in PD. 
Impaired electron transport hampers adenosine triphosphate production and leads to the 
diversion of electrons from their normal electron transport recipients resulting in further 
formation of damaging free radicals (Cassarino et al., 1999). The initial hypothesis that 
mitochondrial complex-I deficiency may be involved in the etiology of PD came from the 
findings that the mitochondrial complex-I inhibitor MPTP causes a clinical syndrome 
indistinguishable from PD and selective dopaminergic cell loss in the substantia nigra 
(SN) (Langston et al., 1983). Subsequently, complex-I activity was assessed and found to 
be significantly reduced in platelet mitochondria in patients with PD compared with 
controls (Hass et al., 1993). Complex-I activity was also reduced in the SN region but not 
in other regions of the brain (Schapira et al., 1990 a, b). 
Several studies suggest that mitochondrial complex-I of the electron transport 
chain (ETC) is responsible for reducing PQ into its radical, which inhibits complex-I 
activity, and finally leading to mitochondrial dysfunction (Dinis-Oliveira et al., 2006). 
Castello et al. (2007) investigated the implications of the mitochondria on exposure to 
PQ. Their results suggested that at least in the rat brain, mitochondria are a principal site 
for PQ2+H2O2 production and that this production requires the presence of respiratory 
substrates. This study found complex-III of the mitochondrial ETC as the main site for 
reactive oxygen species (ROS) production.  
Oxidative Stress in PD 
 Oxidative stress has been hypothesized to be one of the central mechanisms 
linked to both the initiation and the progression of PD. Oxidative stress refers to the 
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undue oxidation of biomolecules leading to cellular damage caused by ROS. The brain 
depends mainly on energy produced from the mitochondria and almost 95% of the 
molecular oxygen that is inhaled is metabolized by the mitochondrial electron transport 
chain. ROS may be formed during a number of cellular processes including 
mitochondrial oxidative respiration and dopamine metabolism. Mitochondria are the 
major source of ROS at the cellular level. Free radicals produce oxidative damage by 
reacting with DNA, lipids and proteins (Betarbet et al., 2002).Various neurodegenerative 
disorders and syndromes are associated with oxidative stress (Behl, 2002). At several 
sites along the ETC are sites of “electron leak” (Arnaiz et al., 1999). These electrons may 
combine with molecular oxygen and thereby form ROS, such as superoxide (O2-) and 
hydrogen peroxide (H2O2) (Halliwell, 1987). The mitochondrial electron transport chain 
produces ROS at complex-I and complex-III. It is suggested that increase in ROS is a 
consequence of the impairment of the mitochondrial respiratory chain (Fluery et al., 
2002). H2O2 is not a free radical but can penetrate cell membranes, making it very toxic 
to the cell (Rhee, 1999). Several studies emphasize the contribution of oxidative stress in 
nigral cell death in PD. This has been demonstrated by postmortem studies in patients 
with PD as well as toxin-induced PD models (Dickson, 2007; Jenner, 2003). The 
evidence of increased oxidative damage includes increased levels of lipid peroxidation, 
DNA damage, and protein oxidation observed in the SN region in patients with PD 
(Zhang et al., 1999). Furthermore, oxidative stress is linked to other cellular processes 
such as cell death, excitotoxicity and mitochondrial dysfunction; therefore it is not easy to 
establish whether oxidative stress is the primary initiating agent or a product of these 
events (Jenner, 2003). 
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Advances in Therapeutic Approaches to PD 
 Much progress has been made in the treatment of PD as a result of advances in 
experimental therapeutics. Many promising therapies are available for PD, and currently 
symptomatic treatments are available focusing on treating the symptoms of the disease. 
These options include dopamine replacement strategies, nondopaminergic therapies, 
surgical approaches and very few neuroprotective therapies that are under research. 
Pharmacological treatment has two main objectives: (1) to increase the activity of 
remaining dopamine synapses and; (2) to suppress the activity in structures that show 
heightened activity in the absence of adequate dopamine action. Levodopa (L-DOPA), 
which is directed toward comfort and support, is the most potent drug for controlling PD 
symptoms. L-DOPA is converted into dopamine in the brain, enhancing effective 
dopamine transmission. Long-term (> 5 years) use of this drug is associated with 
significant complications, such as a “wearing off” effect, L-DOPA-induced dyskinesias, 
and other motor complications, such as fluctuations and dyskinesias and other 
complications (Stern, 2004; Jankovic, 2005). Further, L-DOPA is shown to be toxic to 
dopamine neurons and can produce harmful ROS by oxidative metabolism of dopamine, 
which in turn may hasten the rate of progression of the disease (Olanow, 2008).  
Another extreme form of therapy available is surgery which involves destruction 
of certain parts of the brain (thalamus, the globus pallidus, and the subthalamic nucleus) 
or insertion of electrodes into these areas for electrical stimulation is available for 
patients with PD (Savitt, 2006). This option is usually given to patients with moderate to 
severe PD and/or to patients who are not able to tolerate medications available for this 
disease.  
24 
 
24 
Neuroprotective approaches have shown to be very promising in slowing the 
progression of the disease and limit the extent of neuronal cell loss in PD. The use of 
neurotrophic factors such as neurturin (NTN) (Kordower et al., 2006) and the glial cell 
line–derived neurotrophic factor (GDNF) (Gash et al., 1998), have been reported to 
enhance the survival of midbrain dopaminergic neurons. Bioenergetic compounds such as 
creatine, riboflavin, and CoQ10 are also shown to be neuroprotective agents for PD in 
both animal models and humans (Beal, 2003b). These studies are still under research and 
have not shown any efficacy in slowing down neurodegerative disorders such as PD.  
CoQ10 as a neuroprotective agent. 
The etiology of several neurodegenerative disorders is thought to involve 
impaired mitochondrial function and oxidative stress, which are evident from studies with 
animal models, studies of mitochondria from patients, and analysis of genetic defects. 
Coenzyme Q10 (also known as CoQ10; 2, 3, dimethoxy-5 methyl-6-decaprenyl 
benzoquinone; ubiquinone) is a naturally occurring compound that participates in 
electron transfer in the mitochondrial oxidative respiratory chain for complexes-I and 
complexes-II of the electron transport chain. CoQ10 can accept one electron and be 
converted to an intermediate semi-ubiquinone, which can then accept one electron to be 
converted to its reduced form called ubiquinol (Figure 4). When reduced to ubiquinol, it 
is a powerful antioxidant that prevents oxidative damage from free radicals, including 
oxidation of lipids within the mitochondrial membranes, and protects DNA and proteins 
from free radicals (Ernster, 1995; Geromel et al., 2002; Matthews et al., 1998). Oxidative 
stress burden in the midbrain is usually high under normal conditions due to generation of 
reactive metabolites of DA and is further elevated during aging, especially in patients 
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with PD (Brown et al., 2006; Ernster, 1995). Schults et al. (1997) measured levels of 
CoQ10 in mitochondria from subjects who have PD. CoQ10 levels were found to be 
significantly lower in patients with PD compared to age-matched controls. These findings 
support the idea that increasing CoQ10 levels could be of therapeutic benefit. 
Clinical trials, including an open-label phase trial of CoQ10 in patients with PD, 
have found good CoQ10 absorption and tolerability (Beal, 2003b). A recent study by 
Storch et al. (2007) conducted a randomized clinical trial of a 300 mg dose of CoQ10 in 
131 patients with PD who did not have changes in motor functions and were on stable 
treatment for their condition. Those assigned to the treatment group took 100 mg of 
CoQ10 three times daily for three months, followed by a two-month “washout” period. 
The researchers assessed Parkinson‟s disease symptoms before treatment began, each 
month during treatment, and again after the washout period. The compound was well 
tolerated and the occurrences of adverse effects like viral infection, diarrhea and hearing 
loss were equal between the two groups. This study demonstrated an increase in blood 
levels of CoQ10 in the treatment group, from an average of 0.99 mg/L to an average of 
4.46 mg/L after three months. However, this study failed to show improvement of 
Parkinson‟s disease symptoms as it did not meet its primary or secondary end points, 
which were changes on scales that measured Parkinson‟s disease symptoms and their 
effects on physical and mental functioning. The pharmaceutical applications seem to 
suffer from the lack of solubility and low bioviability, both of which are needed to 
achieve therapeutic effects. 
Although CoQ10 is classified as a lipophilic compound, its degree of solubility in 
lipids is limited, and it is practically insoluble in aqueous solutions. Recently, a water-
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soluble formulation of CoQ10 (WS- CoQ10) was prepared by Drs. M. Sikorska and H. 
Browhy-Borowski of the national Research Council of Canada using a patented protocol. 
In 2006, Bhagava and Chopra reviewed available research data on the absorption, 
metabolism, and pharmacokinetics of CoQ10. They found that in many cases, the soluble 
form of  CoQ10 shows enhanced bioviability in its uptake in cells; moreover, its beneficial 
effects on cardiovascular and neurodegenerative diseases, and its antioxidant properties 
were demonstrated (Bhagava & Chopra, 2006).  
Human neuroblastoma cells pre-treated with WS- CoQ10 have been shown to 
prevent against PQ-induced neuronal cell death (McCarthy et al., 2004). Sandu et al. 
(2003) exposed neurons to 10 μg/ml of WS- CoQ10 for three days. The investigators 
found that this treatment resulted in an increase of cellular ATP levels, with an increase 
of CoQ10 in cellular mitochondria membranes and cell membranes. In addition, they 
found that WS- CoQ10 can prevent against neuronal cell death caused by glutamate 
excitotoxicity (Sandu et al., 2003). Somayajulu-Nitu (2009) reported that prophylactic 
application of a water-soluble formulation of CoQ10 could effectively offset the effects of 
the environmental neurotoxin paraquat. They used a model of paraquat-induced 
dopaminergic neurodegeneration in adult rats that received three weekly intraperitoneal 
injections of the herbicide paraquat. They found increased levels of oxidative stress 
markers and a loss of approximately 65% of dopamine neurons in the substantia nigra 
region. In addition, the researchers found that rats receiving a water-soluble formulation 
of CoQ10 in their drinking water prior to and during the paraquat treatment neither 
developed neurodegeneration nor reduced performance on their behavioural assessment 
(rotorod) than the control paraquat-untreated rats. Given the research discussed on the 
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potential benefits of WS- CoQ10 and protection against neurodegeneration, the current 
study is aimed at further evaluating the efficacy of WS- CoQ10 in rats induced with 
Parkinson‟s disease.  
Serial Reaction Time 
Sequential learning entails learning to organize sequences of behaviour so as to 
anticipate events occurring in a consistent sequential order. Stewart Hulse and colleagues 
initially studied such learning in rats by systematically varying amount of food at the end 
of a long runway over trials and examining rats‟ changes in running speeds over these 
trials as food quantities consistently changed.  Results from a series of studies suggested 
that rats learn to anticipate patterned sequences of events or “serial patterns”. Hulse and 
Dorsky (1977) presented rats with a simple monotonic pattern sequence of 14-7-3-1-0 
food pellets in Experiment 1 which they considered promoted a single “less than” rule to 
describe the relationships of all successive pairs of quantities. Other rats received 
nonmonotonic pattern sequence 14-1-3-7-0 food pellets which would generate a more 
complex combinations of “less than,” “greater than”, and “equal” rules to describe the 
patterns. Rats learned to anticipate (run more slowly down the non-rewarded runway) 
more easily with the simple monotonic than nonmonotonic pattern. In Experiment 2, 
some rats experienced a weaker monotonic pattern 14-5-5-1-0 pellets that was 
intermediate between the monotonic and nonmonotonic pattern sequences given to other 
rats.  These animals learned to adjust their running speeds less easily to weaker than 
stronger monotonic pattern. Hulse and Dorsky (1977) concluded that rats are sensitive to 
pattern structure and can learn the rules that described the structure. In a later experiment, 
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they also showed that rats could generalize a rule from one set of patterns to a different 
pattern (Hulse and Dorsky, 1979).  
 Capaldi and Molina (1979) challenged the theory that rats learned rules by 
maintaining that patterned performance could be accounted by rats acquiring simple 
stimulus associations and generalizations in pattern learning. According to this notion, 
food quantities earlier in a sequence serve as cues for the later food quantities.  Fountain 
and his research team provided clearer evidence that rats learn a simultaneous rule from 
sequential patterns rather than simple successive associations.  For example, Fountain et 
al., (2006) trained rats in an octagonal operant chamber equipped with a retractable lever 
mounted on each wall designated 1-8 in a clockwise fashion. In their typical procedure, 
all levers are presented at the beginning of each trial allowing the rat to press any of the 8 
levers. If the correct lever is chosen, the rat receives brain-stimulation reward (BSR) via 
implanted hypothalamic electrodes. If an incorrect lever is chosen, all levers except the 
correct lever are withdrawn from the box and the rat must make a correct choice to 
receive BSR before continuing to the next trial. Rats were required to learn two patterns 
of successive lever choices, a “perfect” pattern (123-234-345-456-567-678-781-812) and 
one containing a “violation” pattern (123-234-345-456-567-678-781-818). They were both 
identical, but the violation pattern contained a single element at the end of the pattern that 
violated the simple structure. Rats were given 24-element response patterns which can be 
described as composed of either 3-element “chunks” that share a common base “rule” 
within chunks,  usually “+1” rule. In the violation pattern, there is an exception to the rule 
for the last element. Now, the rule is “+2”, which would be a correct response. The 
authors found that rats learn to use combinations of multiple pattern elements to respond 
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properly in a trial and anticipate the violated element. We note that this task requires 
considerable training over several sessions before rats show any reasonable accuracy in 
lever choices.  Although Fountain has successfully used this as a behavioural assessment 
to examine neurological function of  NMDA receptors, a specific type of glutamate 
receptor which plays a critical role in hippocampal learning (Fountain et al. 2000) we do 
not consider this preparation logistically suitable for our goals.  Rather, in reviewing the 
literature on serial pattern learning we discovered a far easier-to-learn serial reaction time 
task initially given to humans and later shown to be similarly easy to acquire by animals.  
The main reasons behind studying sequential learning by using the serial reaction 
time (SRT) task are: (1) sequencing of information and actions is a fundamental human 
ability; (2) sequence learning is an easily studied example of skill acquisition (i.e., 
reaction time and error rates are reliable measures for determining improvement in 
sequential learning; and (3) sequence learning may be a complex form of implicit 
learning.  
Nissen and Bullemer (1987) developed a simple paradigm that now forms the 
basis of much of the research on sequence learning. In this task, human participants sit in 
front of the computer screen and are shown an asterisk which appears in one of four 
locations across the monitor. Participants are instructed to react to the presentation of the 
stimulus by pressing one of the four keys positioned below the stimulus. A correct 
response makes the stimulus disappear and another asterisk later appears in one of the 
other three positions. Location of response follows a pattern whereby the stimuli follow a 
10-trial sequence which is then repeated. The beginning and end of the sequence are not 
marked. Each participant typically receives 10 repetitions of the sequence (100 trials), 
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which makes up a block, and typically a total of four blocks are presented. At the end of 
the fourth block, a fifth block is presented in which the position of the stimuli is 
randomly determined. The dependent variable is reaction time to respond to each 
stimulus (RT), and learning of the sequence is inferred from a reduction in RT over the 
four learning blocks followed by an increase in RT on the fifth block containing a 
random sequence. The RT provides a measure of participants‟ growing expertise in 
performing not only the sequence but also in learning the visuomotor association or 
mapping between the position of the visual cue and the required response. This difference 
in RT between pattern and random trials indicates the extent of learning to fixed pattern. 
Despite the performance difference, some participants are unable to express declarative 
knowledge of the nature of the fixed and random sequences. Consequently, their learning 
is considered to be implicit.  
Nissen and Bullemer (1987) also gave the SRT task to patients with amnesia. 
They found that amnesic patients show these learning patterns despite their lack of 
awareness of the sequence. Willingham (1989) showed that reaction times can be 
improved with repeated sequences even if the subject was not aware of this learning. This 
study used an SRT task similar to that used by Nissen and Bullemer (1987) in which they 
investigated procedural learning in normal subjects. Locurto et al. (2010) examined the 
acquisition of sequence information by cotton-top tamarins (Saguinus oedipus). The 
authors wanted to know what subjects learn in the absence of explicit reinforcement for 
correct responses. Two experiments were conducted using an implicit chaining 
procedure. Visual stimuli were presented serially on a touch screen. Subjects were 
required to touch one stimulus to advance to the next stimulus. These stimuli were 
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presented in a fixed pattern, but learning the pattern was not necessary for reinforcement. 
In experiment 1, five different visual stimuli were presented in the same order on each 
trial, each occurring at any one of the six positions. In experiment 2, the same visual 
element was presented serially in the same five locations on each trial, which allowed a 
behavioural pattern to be correlated with the visual pattern. In addition, two new tests, a 
Wild-Card test and a Running-Start test were used to assess what was learned in this 
procedure. Results indicated that tamarins acquired more information about the 
sequential nature of the stimuli than by the rules of reinforcement. The authors concluded 
that even without explicit reinforcement for correct responding, tamarins can learn 
several features of patterned information, including the sequence position of elements in 
a series and the perceptual characteristics of those elements.   
Domenger and Schwarting (2007) developed a rat version of the human SRT task. 
They trained rats to nose-poke one of the four locations (illuminated nose-poke hole) to 
obtain a reward under sequential conditions. The authors investigated the effects of 
violating a single stimulus position in the series to determine whether the rats still 
attended to the actual stimulus order when confronted with sequence violations. Random 
conditions showed slower reaction times and lower response accuracy compared to fixed 
sequential conditions. In-depth analysis of the incorrect responses showed that most rats 
directed their errors to the position where the stimulus would have normally appeared.  
In the standard serial reaction time task, individuals might learn either the 
perceptual or motor sequence separately or in some combination. Although the SRT task 
is often viewed as a motor learning task, it is not clear that learning is taking place solely 
in the motor domain. The motor theory of implicit sequence learning focuses on 
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responding to each stimulus. This model suggests that individuals learn a sequence of 
manual response movements and this learning is tied to motor-related output (Goschke et 
al., 2001). Goschke et al. (2001) modified the common SRT tasks as follows. In their 
task, four letters (A, B, C, and D) were presented horizontally in discrete locations and 
each letter corresponded to one of the four response keys on the keyboard. In contrast to 
previous SRT tasks, where each stimulus would appear one at a time, all letters were 
presented visually on every trial. Following the visual stimuli, one of the four letters was 
spoken and heard through headphones. Participants were instructed to respond by 
pressing the key directly below the letter they heard. Unlike previous SRT tasks, location 
of stimuli on the computer screen changed with each trial. The change of location altered 
the associated motor response from one trial to the next. Results showed that normal, 
healthy participants demonstrated implicit based sequence learning in the absence of 
spatio-motor sequencing. The serial pattern could be learned as a sequence of motor 
responses with participants learning the correct sequence of response buttons (Robertson, 
2007). Alternatively, the serial pattern could be learned perceptually, that is, as a 
sequence of visual cue positions. Over time, participants would learn to predict the 
position of each visual cue and so would quickly respond to the appearance of the visual 
cue. Dennis et al. (2006) investigated people‟s ability to learn perceptual sequences in the 
absence of motor sequencing, using an SRT task similar to the one used in the Goschke et 
al. (2001) study. Dennis et al.‟s (2006) study concluded that both younger and older 
adults can learn simple first- and second-order sequences in the absence of a spatiomotor 
sequence (i.e., sequence learning can be supported by purely perceptual learning, but this 
only occurs when the SRT task has been modified to remove the motor sequence). With 
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no motor sequence, individuals are forced to learn perceptually. In contrast, when both 
perceptual and motor sequences are available, then learning occurs in both domains. 
Work done by Willingham et al. (1999) tested the hypothesis that implicit sequence 
learning could be supported by purely perceptual information. They concluded that 
sequence learning is not purely perceptual learning. Thus, sequential learning can have 
both motor and perceptual learning. 
While performing the SRT task, individuals acquire the skill of producing the 
sequence, which is shown by the reduction of reaction time over trials for fixed-pattern 
sequences. In these cases, individuals can also acquire an ability to declaratively describe 
the sequence. After performing the SRT task, an individual might be able to verbally 
describe some or all of the sequences contained within the task. Thus, the SRT task is not 
exclusively a motor learning task; it includes an important declarative component and is 
demonstrated by the ability to verbally describe some or all of the sequences within the 
SRT task. Brown et al. (2007) disrupted sequence learning in individuals by having 
participants learn a word list immediately after sequence learning. After 12 hours of 
being tested with SRT and learning a word list, the participants were retested on the SRT 
and word list and then were administered a free recall test of the sequence. The results 
showed that learning a word list immediately after acquiring the SRT disrupted the 
declarative representation of the sequence, thereby reducing participants‟ ability to 
describe the sequence.  
SRT and Brain Processes 
Motor skill learning is supported by a circuit that includes motor cortical and 
subcortical areas such as the striatum and cerebellum (Robertson, 2007). Keele et al. 
34 
 
34 
(2004) analyzed several studies and theories behind the brain processes of the SRT task 
and found that a similar pattern of areas are engaged during learning in the SRT task. The 
prefrontal cortex, striatum and cerebellum all make contributions during this task. Several 
studies report that the medial temporal lobes (MTL) are involved in SRT only for the 
acquisition of high-order sequence learning but not low-order sequence learning. In 
second-order sequences, predicting the next event requires knowing the two immediately 
preceding events (Curran et al., 2007; Schendan et al., 2003). Procedural memory has 
been associated with subcortical structures of the basal ganglia (Eichenbaum et al., 2001). 
Further, Positron Emission Tomography (PET) studies of SRT learning have shown that 
activation changes within the basal ganglia are associated with learning and the parietal 
and temporal cortex (Grafton et al., 1995; Haseltine et al., 1997). Under implicit 
conditions, activation of areas is commonly associated with motor control, including 
motor cortex and subcortical areas in the basal ganglia (Curran, 1998).  
Over the past 20 years many studies using SRT have been performed on primates, 
healthy human subjects, and patients with brain damage (i.e., Huntington‟s disease [HD], 
Alzheimer‟s disease [AD], and Parkinson‟s disease [PD]). These studies attempted to 
detail possible brain mechanisms involved in sequential learning. Knopman and Nissen 
(1991) studied procedural learning in patients with HD using a four-choice SRT task. 
Participants were given a total of five blocks; the first four blocks were of a fixed pattern 
of stimuli and the last block consisted of random pattern of stimuli. Results showed that 
although there was a reduction in reaction time in the fixed sequences compared to the 
random sequences, there was an increased reaction time compared to the healthy controls 
for reaction time for both types of sequences. More importantly, the individual analysis 
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of patients with HD showed that these patients failed to exhibit a sequence-specific 
learning. Knopman (1991) later studied procedural learning in patients with Alzheimer‟s 
disease using the same SRT task. Results showed that both patients with AD and normal 
controls had the same reaction times across the sessions; however, all patients with AD 
lacked the awareness of these sequences.  
A number of studies have examined the performance of patients with Parkinson‟s 
disease using the SRT task. Interest in this group arises from evidence that suggests that 
the basal ganglia, which are compromised in this group of patients, may play a critical 
role in procedural learning. Ferraro et al. (1993) examined implicit memory performance 
using the SRT task in four groups of subjects: (1) healthy and aged individuals; (2) non-
demented individuals with Parkinson‟s disease; (3) individuals with mild Alzheimer‟s 
disease; and (4) individuals with mild cognitive impairment. The SRT task involved four 
blocks of a repeated pattern of a 10-item key press sequence that tapped general skill 
development along with a fifth block of a non-repeated sequence that emphasized the 
impact of switching from a learned set of associations. The researchers found that 
patients with non-demented PD demonstrated less sequence learning than controls in the 
SRT task. Siegert et al. (2006) conducted a meta-analysis of sequential learning in 
patients with PD and found impaired implicit learning in this population. However, it was 
pointed out that these studies were not methodologically consistent. For example, several 
studies lacked the inclusion of random blocks after sequential conditions and did not 
control for the severity of the disease when recruiting participants.  Despite these 
problems, researchers in animal behavior and cognition have begun to use SRT tasks to 
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examine effects of interference with dopamine production on such sequence learning and 
performance in rats. 
Eckart et al (2010) investigated the effects of bilateral neostriatal dopamine 
lesions induced by 6-hydroxydopamine on sequential learning in rats. This study used the 
operant rat version of the human four-choice SRT. The rats were tested on an interference 
test. That is, the rats were presented with a stimulus that switched between a sequential 
and a pseudo-random order every 5 minutes and a violation test in which one sequence 
item was skipped. The lesion group received bilateral intracranial injections of 6-
OHDA.HCl into the striatum, with two injection sites per hemisphere before the start of 
training, which resulted in subtotal dopamine depletions (35–56%) in the medial 
neostriatum. This study also included operated and non-operated control groups. Results 
from this study revealed that the lesioned group showed less response accuracy and 
slower RT than the control groups. During the alternating phases of sequential and 
random stimulus presentations, RT and accuracy of the control group were better during 
sequential sequences when compared to random sequences. In the lesion group, only a 
moderate advantage in accuracy was observed. In the violation test, the control group 
showed an expected increase in RT on the violated positions. In the lesion group, RT did 
not increase, which suggested less automation of sequential behaviour. This study 
concluded that neostriatal dopamine plays an important role in acquiring or maintaining 
sequential behaviour. The current thesis further examines the effects of destruction of 
dopaminergic brain area on rats‟ SRT performance and on the potential to use of this task 
as a diagnostic tool in assessing the neuro-protective effects of post-insult treatment with 
a water soluable formaulation of CoQ10. The neuro-protected group should show no 
37 
 
37 
change in their RT or errors compared to the placebo group in their post-injection 
behavioural assessments. The non-protected group should show increased RT and more 
errors compared to the protected group and the placebo group.  
Objectives 
1. To develop a rat SRT preparation for investigating performance as a function of 
sequence structure 
2. To study the neuroprotective effects of water-soluble coenzyme Q10 (WS- CoQ10) 
by evaluating the behavioural effects on the SRT using the paraquat-induced 
sporadic Parkinson‟s disease model in Long-Evans hooded rats 
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CHAPTER III 
DESIGN AND METHODOLOGY 
Materials 
 Experimental animals. 
Twenty-five male Long-Evans hooded rats, purchased from Charles River 
Breeding Farms, St. Constant, Quebec, were used in this study. Only twenty-four animals 
were used for data analysis, one animal was dropped out of the study. When the rats 
arrived at the facility, they were randomly split into two groups: one that would receive 
injections of PQ (10 mg/kg) and the other that would receive injections of saline. These 
two groups were then further divided into groups based on their water regimen: whether 
they received WS- CoQ10 (50 µg/mL) in their drinking water (H2O) (Figure 5). On 
average, the rate of water consumption for a rat is 10 ml per 100 g of body weight each 
day. An average rat weighing 500 g would therefore consume 5 mg of either WS- CoQ10 
or H2O. The rats were approximately 2 months old and weighed an average of over 300 g 
at the beginning of the study. There were three to four rats per group cage. After each 
experimental session, they were fed 20–25 g of food (Purina Rodent Chow) and its 
specific liquid for 2 hours in individual holding cages only before being returned to their 
large-group holding cage in the colony room. This regimen was necessary for long-term 
maintenance of the rats‟ weight and prevented dominance hierarchies based on the degree 
of neurodegeneration between the paraquat-injected animals and the saline-injected 
animals. This regimen prevented the possibility that the saline-injected rats and/or the 
neuroprotected rats might dominate other rats and gain access to liquid and food. The 
rats‟ specific liquid was freely available in group and holding cages. This regimen 
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maintained rats at approximately 90% of their free-feeding weights over the course of the 
experimental period. Towards the end of the study, the rats weighed between 400 g and 
500 g. Rats in either their individual cages or group cages had access to drinking 
solutions (regular water or with water supplemented with WS- CoQ10). Bottles that 
contained WS- CoQ10 were wrapped in aluminum foil to prevent degradation of the 
compound and were refilled every day. Illumination in the colony room was maintained 
on a reversed 12:12 hour dark/light cycle, and experimental sessions always began within 
3 hours before the beginning of the dark cycle to ensure that these nocturnal animals were 
awake and active during their SRT sessions. The colony room was maintained at 
temperatures of 20°C–24°C. All animal care, procedures, and treatments were approved 
by the University of Windsor‟s Animal Care Committee and were in accordance with the 
Canadian Council for Animal Care Guidelines. 
Water-soluble formulation of CoQ10 (WS- CoQ10). 
Water soluble CoQ10 (WS- CoQ10) was obtained from the National Research 
Council. The WS- CoQ10 was produced through a patented protocol (U.S. patent #6 045 
826), which contained a 2:1 (w/w) ratio of oxidized and reduced forms of CoQ10, 
respectively.  CoQ10 was contained within a water-soluble “cage” composed of 
polyethylene glycol and α-tocopherol (vitamin E). Stock solutions of WS- CoQ10 (50 mg 
of CoQ10 and 150 mg of PTS per mL in phosphate buffered saline) were diluted with 
regular drinking water to a final concentration of 50 µg WS- CoQ10 per mL. 
SRT apparatus 
Three 48.3×22.9×27.9 cm standard operant chambers (Figure 5) were placed in 
separate sound-attenuated chambers. In each chamber, five light-equipped nose-poke 
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holes, each covered by a translucent plastic disk and were arranged horizontally. The 
pellet receptacle was placed on the opposite side of the nose-poke holes, and a house light 
and speaker were attached directly above. The pellet receptacle was attached to a 
dispenser, which delivered sugar pellets. Infrared devices detected entries into the nose-
poke holes and the food receptacle. The whole system was controlled and monitored by a 
program created by the Tech-Support Centre, University of Windsor with LabVIEW 
software. 
Behavioural Assessment 
 Phase 1- Shaping 
The rats were trained on the SRT apparatus and were required to respond to a 
discriminative visual stimulus which in this case, was the illumination of middle of five 
nose-poke translucent keys. Rats were required to poke the key before it was darkened to 
receive a food pellet before being trained on a sequence of lit keys before each 
reinforcement.  Following this initial training, rats were trained to respond to a series of 
illuminated holes before being reinforced; the final level in this experiment was on a 
fixed-ratio schedule of 5 (FR5). During the first 3 weeks of shaping, the rats were trained 
daily for 10–30 min per day. Initially, one hole was illuminated for 20,000 ms and poking 
at this hole was reinforced on a continuous reinforcement schedule (FR1). For each 
illuminated hole that the rat pokes, the rat would get reinforcement. When the rat learned 
to respond at this signal, it was shaped to respond to an FR2, FR3, and finally an FR5 
schedule. A typical trial (FR5) was initiated by a house light which lasted for 5,000 ms. 
Immediately after the house light went off, one of five nose-poke keys was illuminated 
for 20,000 ms. The subject terminated the key by poking the illuminated key. The inter-
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signal interval was 0 ms, at which point the next key was lit for 20,000 ms. After all five 
keys had been poked, the tone (75 dB noise) would turn on for 1000 ms, indicating that 
the reinforcement was ready. The subject would then poke the food receptacle with its 
nose to obtain a reward. The next trial was initiated after the subject obtained 
reinforcement. 
 Phase 2- Pre-injection 
Subjects were then tested using the ABA sequences. The sequences were of two 
types: fixed (A) or random (B). In fixed sequences, one of five nose-poke locations 
(Figure 6) was presented in a fixed order with no repetition (e.g. 31452, 31452 and 
31452). In the random condition, the five nose-poke locations were presented randomly 
with no repetition among the sequences (e.g.13452, 41325, 51234 and 12354). The 
random patterns for each subject were computer generated. Subjects were trained one 
session per day for 15 days. Each session consisted of 300 nose pokes with every fifth 
correct nose poke reinforced. Of the 300 correct nose pokes, the first 100 were of fixed 
sequence (A), followed by a random sequence for 100 nose pokes (B), and finishing off 
with the same fixed sequence of 100 nose pokes (A). For these sequences, the house light 
was on for 5,000 ms and the inter-signal-interval was 1,000 ms. These parameters were 
chosen in these experiments because they were used in previous studies using the SRT. 
The signal light was illuminated for 3,000 ms. The rats‟ latency, or reaction time, to press 
a lit key was measured in milliseconds. If the rats failed to poke a lit key, the signal 
would turn off and reappear after 1,500 ms. This sequence continued until the animal 
poked the lit key. If the animal poked an unlit key while the other key was lit, the lit key 
would be terminated and would turn on after a 1,500 ms delay. Poking an unlit key was 
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labeled  an incorrect choice while failure to respond was designated an omission..During 
this phase, all rats received H2O (tap water) in their individual holding and group home 
cages. 
Phase 3- Post-Injection 
Injection regimes. 
Figures 7 and 8 describe the group allocation and the time line for this phase 
respectively. Previous studies, such as the one conducted by Somayajulu et al. (2009), 
conducted several experiments to induce selective damage to DA neurons in rats‟ SNc. 
For the first experiment, rats were given three intraperitoneal injections of PQ (10 mg/kg) 
to induce selective damage to DA in the SN in mice, used similar protocol to 
(McCormack et al., 2002). In the second experiment, rats were given eight intraperitoneal 
injections of a combination of PQ (10 mg/kg) and the fungicide MB (30 mg/kg), same 
regimens as per (Thiruchelvam et al., 2000a; Thiruchelvam et al., 2000b). These 
treatment regimens were fatal to a large number of rats during injections and were 
discontinued. Since the PQ and MB regime was not tolerated by the rats, Somayajulu 
(2009) decided to use eight injections of 10 mg/kg PQ alone twice a week for four weeks. 
This regime was toxic to the rats, and the experiment was discontinued. In the final 
experiment, rats were given five injections of PQ to yield greater neuronal loss than in the 
three-injection regime. In all of the above experiments, rats were divided into six groups. 
These groups included saline water, saline placebo, saline WS- CoQ10 PQ-water, PQ-
placebo, and PQ-WS- CoQ10. The rats were fed drinking water supplemented with their 
treatments after 2 weeks of arrival to the facility. In her pilot research, Somayajulu found  
greater neuronal loss when the rats were injected five times compared to three times. 
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Since the five-injection regime yielded greater neuronal loss, the current experiment used 
this schedule.  
In the current study, subjects were randomly divided into three groups (Figure 7), 
with the following number of subjects in each: (i) paraquat and WS- CoQ10 group (n=12), 
(ii) paraquat and H2O group (n=6), and (iii) saline and H2O group (n=7). This experiment 
was designed to study only the therapeutic effect of WS- CoQ10. The number of subjects 
for each group was determined by the research team from the biochemistry department at 
the University of Windsor that was also responsible for injection and post-mortem 
protocols (Facecchia et al., 2011, in progress). After the collection of 15 days of baseline 
data (pre-injection phase), the rats were injected with either 10 mg/kg intraperitoneal 
paraquat injections or saline injections every five days for a total of five injections. 
During the time of injections, subjects were fed tap water (H2O), and were not run on the 
SRT task. Immediately after their fifth injection, the 12 rats that received paraquat were 
fed WS- CoQ10 to investigate its therapeutic effects in halting any post-injection  PQ-
induced neurodegeneration. The remaining rats were fed with H2O. After three days of 
the last injection, the subjects were run through the SRT protocol for another 15 days. 
Each subject was given the same sequence as previously indicated in the preinjection 
phase. After conducting the postinjection behavioural studies, the rats were dissected, and 
tissues were collected for histochemical analyses as part of Katie Facecchia‟s master‟s 
thesis at the University of Windsor. We note that one rat in the PQ+WS-CoQ10 group 
failed to acquire the SRT task during baseline training was not further tested on this task 
during the remainder of the study.  Thus the PQ+WS-CoQ10 group was reduced to 11 rats 
so that SRT performance was assessed and analyzed on 24 animals.  
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Statistical Analysis 
Individual response types and reaction times were analyzed. The following 
response types were used: (a) correct nose-pokes (responses to illuminated holes), (b) 
incorrect nose-pokes (responses to non-illuminated holes), and (c) omissions (no 
response during a lit key). The reaction time (ms) elapsed between the onset of the 
stimulus and the nose-poke of each correct response was normalized to reduce variation. 
This was done by dividing 1,000 by the reaction time for each rat to each signal. These 
reciprocal RT values were then averaged over blocks of three days for each signal at each 
block of fixed and random sequences and then reconverted into normalized mean RT 
scores by dividing the mean reciprocal RT by 1000 of each rat. The various two-way and 
three-way Analyses of Variance were conducted on rats‟ normalized mean RTs as 
described in the results section.  Each rat‟s total number of omissions and total number of 
incorrect choices over all pre-and post-injection sessions and over each block of three 
sessions within each pre- and post-injection phase for fixed and random sequences were 
also analyzed by two- and three-way ANOVAs respectively. All statistical analyses were 
calculated with IBM SPSS (version 19) software. For this and all other analyses a 
significance level used was p < .05.  
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CHAPTER IV 
ANALYSIS OF RESULTS 
Reaction Time 
The means of each rat‟s normalized reaction time (RT) for each session‟s signal 
position in from each within-session block of sequences (1
st
 fixed, 2
nd
 random, 3
rd
 fixed) 
were calculated in three ways.  1.) To determine RT as a function of signal position, we 
calculated their mean signal RTs for each position for each of the three within-session 
blocks of sequences collapsed over all sessions in each phase. We separately analyzed 
rats‟ pre-injection and post-injection data by separate three way ANOVAs (3 groups x 3 
sequence blocks x 5 signal positions).  2.) To determine any changes in SRT performance 
over training in the pre-and post-injection phases, we calculated each rat‟s mean 
normalized signal RT for each within-block of sequences (collapsed over signal 
positions) for each successive block of three sessions (5 blocks).  We conducted a 
separate three-way ANOVA (3 groups x three sequences x five blocks) for each phase to 
determine whether patterns of post-injection SRT differed from those found in the pre-
injection phase.  3.) Finally we calculated each rats mean normalized signal RT for each 
within-session block of sequences collapsed over signal position and sessions that 
allowed us to directly statistically compare data from  pre-and and post-injection phases 
as a function of groups and sequence type.  We carried out a three-way ANOVA (3 
groups x 3 sequences x 2 injection phases).   
1.) Signal RT as a function of Signal Position and Sequence.  Figure 9 
summarizes data describing these functions during the pre-injection phase.  These data 
were collapsed over groups because as expected no significant effects for this factor were 
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uncovered.  A similar summary of the post-injection data are also not shown for reasons 
already discussed.   As seen in this figure and supported by significant main effect for 
sequence, F (2, 42) = 25.453, p < 0.001, rats developed longer RTs during the middle 
within-session blocks of random sequences than during either of the within-session 
blocks of fixed sequences.  Rats also reduced their RTs over signal positions within each 
within-sessions block of sequences but demonstrated greater declines during  the fixed 
than random sequence blocks.  These observations were confirmed by a significant main 
effect for signal position, F (4, 84) = 21.365, p < 0.001, and a significant interaction 
between sequence and signal position, F (8, 168) = 12.214, p < 0.001.  
2.) Signal RT as a function of sequence type and successive 3-session blocks.  
Figures 10A and 10B summarize mean signal RTs for each sequence condition for each 
group over successive three-session blocks during the pre- and post-injection phases 
respectively. During the pre-injection phase, as seen in Figure 10 A and confirmed by a 
main effect for blocks of sessions, F (4, 84) = 4.380, p = 0.003, rats decreased their RTs 
over blocks during each type of session.  Their decline within the random sequences 
appeared somewhat less steep but this observation was not statically supported by any 
interaction between blocks and sequence type, F (8, 168) =1.067, p = 0.388.  A 
significant main effect for sequence type, F (2, 42) = 18.560, p < 001, not surprisingly 
replicated that seen in the initial analysis.  As seen in Figure 10B, rats no longer 
displayed any further declines in signal RTs over post-injection blocks of sessions but 
continued to display greater RTs during random than fixed sequences as confirmed by a 
significant main effect for sequence type, F (2, 42) = 22.189, p < 001. No significant 
interaction between block and sequence was obtained, F (1, 16) = 1.561, p = 0.140.  Of 
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particular importance is that fact no obvious overall differences between groups were 
observed  during this phase nor did group significantly interact with sequence, F (4, 42) = 
0.531, p = 0.714.  
3.) Pre-injection vs post-injection RT comparisons as functions of group and 
sequence type.  Figure 11 shows the overall mean RT for each group during each phase 
as a function of sequence type.  We note that no apparent or significant effects for groups 
were obtained for this analysis, F (16, 168) = 0.927, p = 0.540.  The only apparent effect 
was that rats displayed generally lower RTs in the post-injection phase but this 
observation was not supported by main effect for phase, F (4, 42) = 0.587, p = 0.674.  
Number of Errors 
Error rates were either omissions or incorrect nose pokes (to an unlit key in the 
presence of a lit key).  The means of each rat‟s error rates for each type of error for each 
within-session block of sequences (1
st
 fixed, 2
nd
 random, 3
rd
 fixed) were calculated. We 
calculated mean number of incorrect choices and mean number of omissions for each of 
the three within-session blocks of sequences collapsed over all sessions in each phase. 
We separately analyzed rats‟ pre-injection and post-injection data by separate three way 
ANOVAs (3 groups x 3 sequence blocks x error type).  This was done for both omissions 
and incorrect choices separately.  To determine any changes in SRT performance over 
training in the pre-and post-injection phases, we calculated each rat‟s mean errors for 
each type for each within-block of sequences for each successive block of three sessions 
(5 blocks).  We conducted a separate three-way ANOVA (3 groups x three sequences x 
five blocks) for each phase to determine whether patterns of post-injection SRT differed 
from those found in the pre-injection phase.   
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There were significantly more omissions compared to incorrect choices, as shown 
in Figure 12: F (2, 18) = 17.843, p = 0.00. As shown in Figure 13A, when analyzing 
omissions in more detail in the pre-injection phase, the 15 sessions were broken down to 
three-session blocks. ANOVA was conducted for 3 (groups) by 3 (sequence conditions) 
by 5 (three-session blocks). Results were not significant for blocks: F (4, 84) = 0.690, p = 
0.601. The same analysis was conducted for post-injection data, as shown in Figure 13B. 
Similarly, results were again not significant for blocks: F (16, 168) = 1.226, p = 0.253; 
however, sequence was found to be significant: F (2, 42) = 4.367, p = 0.019. An in-depth 
analysis of the sequence types revealed that the rats made significantly fewer omissions 
during their first fixed sequence than during the random sequence or the final fixed 
sequence, Fs (2, 21) = 8.891; 6.969, p = 0.007; 0.015.  Differences in omissions between 
the random and third fixed sequence were not significant, F (2, 21) = 1. 032, p = 0.321. 
As shown in Figure 14, when directly comparing omissions between the pre-injection and 
post-injection phases, no significant interactions among sequence type, group, and 
blocks: F (4, 42) = 1.359, p = 0.264 occurred but a main effect for  sequence type was 
significant: F (2, 42) = 4.170, p = 0.022. 
When looking at three-session blocks (acquisition data for incorrect responses for 
preinjection, as shown in Figure 15A), results were not significant for sequence type and 
groups: F (16, 168) = 1.594, p = 0.075. Sequence type was significant: F (2, 42) = 
12.450, p = 0.000. The same analysis was performed for post-injection data, as shown in 
Figure 15B. No significant results were obtained for blocks: F (4, 84) = 0.817, p = 0.518. 
Sequence type however was found to be significant: F (2, 42) = 17.907, p = 0.000. An in-
depth analysis of sequences for postinjection data revealed a significant effect for the 
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random sequence and overall significant decline in the mean number of incorrect choices 
over blocks: F (4, 84) = 2.846, p = 0.029. In addition, a separate analysis within each 
block of sequences revealed a significant effect for group in the first fixed sequence: F (2, 
42) = 6.826, p = 0.005. There were more errors with the paraquat and water group 
compared to the other groups (saline group and paraquat and CoQ10 group).  
When comparing omissions between the two phases, pre injection and post 
injection, as shown in Figure 16, there were no significant interactions among sequence 
type, group, and blocks: F (16, 168) = 0.919, p = 0.549. Again, sequence type was found 
to be significant: F (2, 42) = 16.871, p = 0.00. There were more errors for the random 
sequences versus the fixed sequences. These tests may not have sufficient power to detect 
group differences.  
Histochemistry 
Histochemical assays from Phase 3 are not yet available from Facecchia‟s 
master‟s thesis (2011) at the University of Windsor biochemistry department. 
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CHAPTER V 
DISCUSSION 
Although considerable evidence has shown that the development of PD is a result 
of a gene–environment interaction, exposure to environmental toxins has been a major 
focus in current research (Di Monte, 2003). In particular paraquat (PQ), a herbicide, has 
been linked to the incidence and progression of PD (Castello, 2007). The current study 
was designed in part to assess a PQ-induced model of PD in Long-Evans hooded rats and 
to evaluate the neuroprotective properties of water-soluble coenzyme Q10 using the serial 
reaction time task. Reaction time and error (omissions and incorrect choices) were 
measured as a function of sequence structure.  
In the SRT task, when the location of stimuli followed a repeated fixed sequence, 
rats‟ reaction times decreased dramatically. The improvement of reaction time over trials 
in the same session was due to learning of the specific sequence. However, the same 
improvement occurred for the random sequences. In the random condition, the individual 
stimulus–response relations do not allow prediction of subsequent ones, but in the fixed 
condition, stimulus-response relations are highly predictive. Thus, it can be assumed that 
enhanced performance under sequential conditions reflects the establishment of a higher-
order motor plan (Hoffmann & Koch, 1998). Domenger and Schwarting (2007) interfered 
with these cognitive mechanisms through violations of well-trained sequences by 
replacing only one specific position in the FR schedule. They found that the major effect 
of this violation was an increase in reaction times at the violated position. These findings 
suggested that the SRT was an automated task but still required some attention to the 
ongoing stimuli. This method of introducing violations might be of importance when 
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using this task in neurodegenerative disorders. It might show strong effects between the 
disorder of interest and the placebo group.  
Important methodological differences exist between human and nonhuman 
preparations. In SRT task experiments with humans, the experimenter can use verbal 
instructions to communicate to the subjects, encouraging them to perform the task as 
quickly and accurately as possible. This cannot be done with nonhuman subjects where 
the experimenter must communicate the objectives nonverbally. With the development of 
a simple paradigm of studying SRT, variations in methodology make comparisons among 
studies difficult. For example, simple parametric manipulations, such as varying the 
response to stimulus interval, can influence the amount of learning (Willingham et al., 
1997) (i.e., if this interval was too long, these animals do not express learning). Evidence 
suggests that multiple forms of representations exist even within implicit learning (Seger, 
1998). A study by Heindel et al. (1989) demonstrated a double dissociation between 
patients with Huntington‟s disease and patients with Alzheimer‟s disease in implicit 
motor learning and implicit perceptual learning. Heindel and colleagues suggested that 
deficits in the motor learning task were correlated with the amount of dementia in these 
patients, which suggests that implicit learning can affect multiple levels and different 
neural structures.  
For phase 3, when comparing the different groups, (a) paraquat and WS- CoQ10, 
(b) paraquat and H2O, and (c) saline and H2O,  there were no RT differences among 
groups . There are several possibilities why this might have occurred. One possibility is 
that not enough paraquat reached the CNS to kill enough dopaminergic neurons in the SN 
region. The second possibility could be that five weeks was not enough time to cause cell 
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death in these rats. Lastly, the therapeutic effects of the neuroprotectant, WS- CoQ10, may 
not have been observed due to the short period of administration to the rats.  
Parkinson‟s disease (e.g., tremor, impaired facility of movement, rigidity, and loss 
of postural reflexes) allows for the possibility that patients with PD are capable of 
sequence learning but are simply unable to demonstrate this learning through a decrease 
in reaction time over trials (Westwater et al., 1998). One concern of using the motor 
version of the SRT task is that the performance of PD patients may be seriously 
compromised by the motor difficulties that characterize this disease. This study examined 
the performance of patients with PD (n=13) and healthy controls (n=11), matched for 
verbal fluency on a verbal version of the SRT task, where the standard button-pressing 
response was replaced by a spoken response. They found that the PD group demonstrated 
less sequence learning than the controls, independent of age and severity of illness.   
Evaluation of the PQ-Induced PD Model and Susceptibly of the SN 
 Five injections of PQ (10 mg/kg) or placebo was injected into the rats. No 
fatalities were reported. An important aspect to consider in the effectiveness of the five-
injection regime was to determine whether the amount of PQ administered to the rats was 
enough to selectively target and cause neuronal cell death in the substantia nigra while 
leaving other brain regions and organs unharmed. Unfortunately, due to technical 
difficulties, these staining results were not obtained (Facecchia, 2011, pending thesis). 
However, previous research found that PQ selectively targets dopaminergic neurons in 
the substantia nigra by exerting its toxic effects through the production of ROS (Dinis-
Oliveira et al., 2006). Several authors have suggested that DA neurons are susceptible to 
the oxidative damage caused by toxins due to pre-existing vulnerabilities in the neurons. 
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Dopaminergic neurons are already under considerable oxidative stress because the 
metabolisation of dopamine involving MAO produces hydrogen species (H2O2) as a by-
product (Dinis-Oliveira et al., 2006). Furthermore, H2O2 is converted by Fenton reactions 
to produce highly toxic hydroxyl radicals in the presence of the high levels of iron 
usually present in the SN (Youdmin et al., 1989). Postmortem analysis of PD patients has 
confirmed the presence of high levels of iron in the substantia nigra (Dexter et al., 1989). 
It is evident that PQ-induced redox cycling within the SN may exceed the oxidative 
defences of the DA neurons, thus proving detrimental for the neurons.  
 Although rodent models are advantageous because subjects are easily accessible, 
a varied susceptibility exists  between species in their response to neurotoxins. For 
example, mice are more susceptible to MPTP than rats. Furthermore, age, gender, and 
body weight also play important roles in determining the sensitivity of an animal to 
neurotoxins (Przedborski & Vila, 2001). Differences have also been found among 
different strains of rats. For example, Lewis rats require two-fold higher dosing of 
oxidopamine than Fischer or Sprague-Dawley rats. Interestingly, when rotenone is 
administered in Lewis rats, less variability and more consistency are exhibited compared 
to Sprague-Dawley rats (Betarbet et al., 2002). Evidence of neuroprotection in rodents 
does not guarantee similar results in humans (Emborg, 2004). The advantage of using an 
animal model is to obtain a phylogenetic perspective about the odds of success when 
translating a therapy to humans. Obviously these models must continue to be refined in 
order to improve techniques for evaluating neuroprotective compounds.  
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WS- CoQ10as a Therapeutic Agent in Rats 
Coenzyme Q10 is a hydrophobic and is localized in the inner mitochondrial 
membrane. Previous studies have used oil formulations of CoQ10. Since CoQ10 is very 
hydrophobic, cells cannot absorb it easily. Recently, water-soluble CoQ10 containing both 
the oxidized and reduced forms was formulated and prepared by Drs. M. Sikorska and H. 
Browhy-Borowski. Water formulations of CoQ10 are readily absorbed by the cells when 
added to tissue culture media, making it possible to study the mechanism by which CoQ10 
offers protection against oxidative stress. An increase in CoQ10 content in the 
mitochondrial membranes and cell membranes has been observed in cells pre-treated 
with CoQ10 (Sandhu et al., 2003). WS- CoQ10 may be exerting its neuroprotective effects 
by acting as an antioxidant and reducing the amount of harmful reactive oxygen species 
by scavenging free radicals (Beal et al., 2003). In vivo studies have shown the ability of 
the enzyme to prevent the reduction of ATP levels. Clinical trials have evaluated oil-
soluble CoQ10 in PD patients and found a fair amount of absorption and tolerance of 
CoQ10 but cautioned that very high doses were needed to achieve any positive effects 
(Shults et al., 2004). However, no efficacy trials have proved that CoQ10 stabilizes 
symptoms of PD with this other formulation. WS- CoQ10 is an improved formulation, as 
it is a stable water-soluble complex that can be administered orally. Sikorska et al. (2003) 
found elevated plasma levels of WS- CoQ10 in rats fed with this compound.  
One of the major objectives of this study was to assess the neuroprotection 
provided by WS- CoQ10 as a therapeutic agent in rats. Data from Facecchia (2011, 
pending thesis) have yet to be obtained. 
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Susceptibility of Rats to PQ Toxicity and Protection by WS- CoQ10 
In the current study, the susceptibility of paraquat toxicity in rats are being 
assessed by another colleague participating in this project.  To data these results have not 
been obtained. However, in previous studies, Saint-Pierre and colleagues (2006) found a 
significant loss of DA neurons observed in the SNc after 6 weeks of only two toxin 
injections (30 mg/kg) in 6-month-old rats. Shultz and colleagues (1999) have attributed 
the greater effectiveness of CoQ10 in aged animals as a result of the decline in brain levels 
of CoQ10 with age. The decline of CoQ10 levels can be attributed to reduced synthesis of 
age-dependent increase in lipid peroxidation (Beyer et al., 1985). 
Challenges Associated in Finding a Neuroprotective Therapy for PD 
There are limitations to current models used for neuroprotection. Cell cultures are 
used in a variety of research. They are especially important when drugs are first tested to 
determine whether they can protect cells from a variety of toxins. Cell culture models do 
not provide insight into how a drug will behave in an organism. To evaluate the capacity 
of drugs to protect DA neurons from toxic insults, its side effects and treatment-
associated complications in vivo models are indispensable. 
 One of the challenges in developing neuroprotective strategies is that the exact 
causative factors of PD remain unclear. Most cases of PD are sporadic and of unknown 
etiology. Knowing the precise mechanism of PD would then allow the identification of 
probable targets for the development of neuroprotective agents (Olanow et al., 2008). 
Which, if any, of the proposed mechanisms in PD is primary and is responsible for cell 
death remains uncertain. As discussed earlier, many mechanisms cause cell death in PD. 
Studies have shown that patients carrying the same gene mutation and who are family 
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members may exhibit different clinical symptoms and different pathology (Olanow et al., 
2008), implying that a combination of various neuroprotectants acting simultaneously on 
different mechanisms might be required to achieve neuroprotection.  
Future Work 
In future studies, the present test might be useful to study and distinguish brain 
mechanisms critical for skill and attention. Electrophysiological and brain imaging 
studies have shown that sequential learning and performance are correlated with a 
number of changes in neuronal activity, including basal ganglia structures, cerebellum, 
and various cortical areas, especially within the motor cortex ( Keele et al., 203; Saing-
Cyr 2003). The use of violations in humans yield activations in the basal ganglia as 
shown in the fMRI (Huettel et al., 2002). A role of the basal ganglia has also been 
specifically demonstrated with lesion studies in rodent models using the SRT (Keel et al., 
2003). The use of this SRT task in Parkinson‟s disease may be of value since impaired 
sequential learning reflects the loss of dopamine function within the basal ganglia.  
Due to the lack of histochemical results, we cannot conclude that there was any 
neuroprotection by CoQ10 or if paraquat did indeed cause a loss of dopamine neurons in 
these rats. Once a standard protocol has been developed to count the cells in the brain 
tissue of rats, it would be beneficial to run this test again to see whether there was any 
neuroprotection by CoQ10 using the SRT.  
Therapy for PD begins after diagnosis, by which time a large number of DA 
neurons have already been lost. For a candidate to be considered as a good 
therapeutic/restorative agent, it should be able to arrest the further loss of neurons and 
thereby prevent the progression of this disease. Further experiments will be needed to 
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confirm our studies aimed at evaluating the potential effects of WS- CoQ10 as a 
therapeutic intervention in PD. Since PD is a slowly progressive disease, it would be 
important to have a longer-term follow-up of these rats in the SRT task. This follow-up 
may be needed to identify clinically meaningful benefits to the administration of WS- 
CoQ10.  
WS- CoQ10 is now being developed to cross the blood–brain barrier (BBB), an 
evaluation of the amount of WS- CoQ10 that diffuses across the BBB and furthermore, 
the amount taken up by the mitochondria would be helpful findings. More research is 
required in this area. The next steps would be to determine if this compound is safe for 
human consumption, as this would be a potential candidate for clinical trials.  
Conclusion 
It is of value to have an animal model of a human implicit memory task for which 
there is already reasonable evidence in humans that it reflects a motor skill. In the current 
study, rats were more efficient on 5CSRT under fixed rather than random sequences for 
RTs and incorrect choices. This effect occurs for RTs as a function of signal position and 
also when collapsed over positions.  
While we did not demonstrate significant RT differences between the 
neuroprotected group and the non-neuroprotected group, it remains an open question as 
to whether this represents a true absence of learning differences between the groups or 
rather a problem of sensitivity of our testing methods. Repeating this study with probe 
sequences containing single violations might produce more reliable effects as a function 
of PQ-induced neurodegeneration similar to that reported by Eckart et al (2010).  The fact 
that our PQ+H2O group did produce more incorrect choices during the first third or each 
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session than the other two groups is interesting and needs to be replicated in further 
research.  The questions we need to determine are whether such a difference resulted 
from the inclusion of random sequences mid-way through the session or if it merely 
reflects poorer performance at the beginning of a session.  The fact that this effect 
emerged over blocks suggests that neuro-degeneration of domapine areas may have 
continued to progress in these animals but was halted by post-injection treatment with 
WS-CoQ10.  
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FIGURES 
 
 
 
 
 
 
 
 
 
 
Figure 1. Motor components of the human basal ganglia (Purves 2001). Coronal section 
through the brain showing anatomical locations of structures involved in the basal ganglia 
pathway. Most of these structures are in the telencephalon, although the substantia nigra 
is in the midbrain and the thalamic and subthalamic nuclei are in the diencephalon.  
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Figure 2A. The basal ganglia circuitry: the direct pathway (Purves 2001).  
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Figure 2B. The basal ganglia circuitry: the indirect pathway (Purves 2001). 
 
 
 
 
Figure 3. Catecholamine synthesis. Dopamine functions as both a neurotransmitter and a 
precursor for other catecholamines (Wurtman 1980).  
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Figure 4. The oxidized and reduced forms of CoQ10 (Chew 2004).  
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Figure 5. Serial reaction time task operant chamber. 
 
 
Figure 6. Nose Poke Key Locations 
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Figure 7. Rat groupings based on the injection regime and water supplementation. 
 
Figure 8. Schematic outline for the three phases.  
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Figure 9. Normalized average RTs plotted as a function of sequence for each signal 
position over pre-injection trials. 
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Figure 10. Rats‟ acquisition curves for normalized average RTs plotted as a function of 
sequence for 3-session blocks.  
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Figure 11. Normalized average RTs plotted for both pre-injection and post-injection   
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Figure 12.  Overall error data for both misses and incorrect choices as a function of 
sequence.  
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Figure 13.  Rats‟ acquisition curves for mean number of omissions as a function of 
sequence structure over 3-session blocks.  
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Figure 14.  Mean number of omissions for both pre and post-injection as a function of 
sequence 
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Figure 15. Rats‟ acquisition curves for mean number of incorrect choices as a function of 
sequence structure over 3-session blocks.  
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Figure 16.  Mean number of incorrect choices for both pre and post-injection as a 
function of sequence. 
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